Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal
Rhea-AI Summary
Aclarion (Nasdaq: ACON) responded to Echo Lake Capital’s unsolicited offer to acquire the company for $4.00 per share in cash plus contingent value rights. The Board will carefully evaluate the proposal and has also authorized a share repurchase program, citing conviction in Aclarion’s long-term opportunity.
Positive
- Echo Lake Capital submitted an unsolicited acquisition proposal at $4.00 per share plus contingent value rights
- Board committed to carefully reviewing Echo Lake’s proposal in shareholders’ best interests
- Authorization of a share repurchase program signaling confidence in Aclarion’s valuation and prospects
- Board highlights diversified expertise across healthcare, regulatory affairs, technology investing, and medical technology scaling
Negative
- None.
News Market Reaction – ACON
In the May 28 session, ACON gained 0.96%, reflecting a mild positive market reaction. Argus tracked a peak move of +9.4% during that session. Argus tracked a trough of -13.9% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was exceptionally heavy at 19.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Trial site expansion | Positive | -3.7% | Added first private-practice site to 300-patient CLARITY randomized trial. |
| May 06 | Management hiring | Neutral | +2.5% | Inducement stock option grant to new Commercial Director, Western U.S. |
| May 05 | Commercial agreement | Positive | -3.3% | Second commercial agreement with Weill Cornell to expand Nociscan use. |
| Apr 30 | Q1 earnings update | Positive | +1.8% | Reported strong Q1 with 196% scan growth and announced share repurchase. |
| Apr 28 | Leadership appointment | Neutral | +0.0% | Appointed Commercial Director, Western U.S., to drive Nociscan adoption. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive updates (trial progress, commercial deals, strong Q1) have often seen muted or negative next-day price reactions, indicating a pattern of market skepticism toward good news.
Over the past two months, Aclarion reported strong Q1 2026 metrics, including scan volume growth of 196% year-over-year and a $2.5M share repurchase, alongside $19.0M in cash and 64 issued/pending patents. It expanded Nociscan adoption via new commercial agreements and trial sites, and added a Commercial Director for the Western U.S. Despite these developments, several positive clinical and commercial headlines on May 5 and May 7 saw negative next-day moves. Today’s board response to a $4.00-per-share proposal and emphasis on repurchases arrives against that backdrop of cautious trading.
Key Terms
contingent value rights financial
biomarkers medical
augmented intelligence technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to the press release issued by Echo Lake Capital and its offer to acquire the Company for
Aclarion's Board of Directors and management team are committed to acting in the best interests of the Company and all of its shareholders. We regularly review our strategic priorities and evaluate opportunities to enhance value for all stakeholders. To that end, the Board of Directors will carefully review and evaluate Echo Lake’s proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders.
The Board authorized a share repurchase program underscoring our conviction that Aclarion's current market valuation does not fully reflect the strength of our platform or the long-term opportunity ahead. This action also reflects our commitment to deploying capital in ways that serve the interests of all shareholders while continuing to invest in our business.
The Company notes that the Echo Lake communication contains numerous assertions regarding governance and other matters that lack important context and are presented in a manner that the Board believes is misleading. Aclarion's Board comprises seven highly qualified directors with relevant expertise in healthcare, regulatory affairs, technology investing, payer contracting, public company leadership and scaling medical technologies. The Board is committed to ongoing Board enhancement and regularly evaluates its composition to ensure it brings the fresh perspectives and appropriate skills necessary to drive value creation for all Aclarion shareholders. Accordingly, five new directors have been appointed within the last six years, all of whom bring diverse perspectives that directly align with Aclarion’s strategic priorities.
Goodwin Procter LLP is serving as legal counsel for Aclarion.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains information that may constitute forward-looking statements, including with respect to Aclarion’s Board of Directors, Aclarion’s business strategy, and other matters. Forward-looking statements are not guarantees of future performance or results. Forward-looking statements can be identified by the fact that they do not relate strictly to historic or current facts and often use words such as “anticipate,” “estimate,” “expect,” “believe,” “will likely result,” “outlook,” “project” and other words and expressions of similar meaning. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, those set forth in the “Risk Factors” and related discussions in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and Aclarion undertakes no duty to update these statements.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jenna Shinderman
Sodali & Co
Jenna.shinderman@sodali.com
